A5018335569- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Cancer Mechanisms and Therapy
- Renal cell carcinoma treatment
- Advanced Radiotherapy Techniques
- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Liver Disease and Transplantation
- Gastric Cancer Management and Outcomes
- Apelin-related biomedical research
- Veterinary medicine and infectious diseases
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Liver physiology and pathology
- Adrenal Hormones and Disorders
- Cancer Genomics and Diagnostics
- Sepsis Diagnosis and Treatment
- Neuropeptides and Animal Physiology
- Renal Diseases and Glomerulopathies
- Radiation Therapy and Dosimetry
- Ferroptosis and cancer prognosis
University of Duisburg-Essen
2022-2025
Essen University Hospital
2022-2025
Deutschen Konsortium für Translationale Krebsforschung
2023
Technical University of Munich
2019-2021
Klinikum rechts der Isar
2019-2021
Evaluation of the efficacy and safety atezolizumab/bevacizumab in a real-world HCC cohort, including patients with impaired liver function prior systemic therapy.
Objective: To evaluate the prognostic value of pre-therapeutic inflammatory markers before transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in treatment hepatocellular carcinoma (HCC). Methods: A total 155 patients (81% male, median age: 68 years) who underwent first-time DSM-TACE between 07/13 and 06/22 were included study. Inflammatory indices dichotomized using values. Cox proportional hazard model for univariate (UVA) multivariate (MVA) analyses (hazard...
Atezolizumab/bevacizumab (atezo/bev) and lenvatinib have demonstrated efficacy as first-line therapies for hepatocellular carcinoma (HCC). However, vascular endothelial growth factor (VEGF) inhibition with these may be associated the risk of bleeding thromboembolic events. In this study, we evaluated safety focus on events atezo/bev
Immune checkpoint inhibitor (ICI)-based regimens are transforming the landscape of hepatocellular carcinoma (HCC) treatment. We describe effect combined ipilimumab and nivolumab in patients with advanced HCC after failure prior ICI-based combination treatments.
Introduction: Immunomodulating effects of Helicobacter pylori (H. pylori) have been shown to inhibit antitumor immunity. Resistance immune checkpoint inhibitor (ICI)-based therapies is common among patients with hepatocellular carcinoma (HCC). This study aimed assess the effect H. on outcomes ICI in HCC. Methods: We conducted a multicenter HCC across broad range treatments. Patients received either ICI-based combination regimens or sorafenib-based therapy. serostatus and virulence factors...
Die Prävalenz der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung (MASLD) nimmt weltweit kontinuierlich zu. progressive Form, die assoziierte Steatohepatitis (MASH), stellt in fibrotischen Leber einen global führenden Risikofaktor für Entwicklung eines hepatozellulären Karzinoms (HCC) dar. Frühdetektion des HCC den entscheidenden Faktor das Gesamtüberleben bei MASH-Patienten dar, unabhängig vom Vorliegen einer Zirrhose. Daher ist es besonders dieser spezifischen...
Atezolizumab plus bevacizumab is the standard of care for first-line systemic therapy advanced hepatocellular carcinoma (aHCC). Data on efficacy and safety atezolizumab in patients with aHCC who have received prior are not available.
Background: Immunotherapy-based combinations are currently the standard of care in systemic treatment patients with HCC. Recent studies have reported unexpectedly long survival lenvatinib (LEN), supporting its use first-line for This study aims to compare real-world effectiveness LEN atezolizumab/bevacizumab (AZ/BV). Methods: A retrospective analysis was conducted evaluate and safety frontline AZ/BV or therapy advanced HCC across 18 university hospitals Europe. Results: The included 412...
Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance absorbed doses for nontumor liver tissue are assessed by calculating the mean dose whole (AD-WNTLT), which may be limited its neglect of nonuniform distribution. Thus, we analyzed whether voxel-based could more accurate predicting hepatotoxicity HCC patients undergoing radioembolization. Methods: In total, 176 were available retrospective...
Recommended treatment options for advanced-stage hepatocellular carcinoma (HCC) include systemic therapy (ST) and trans-arterial radioembolization (TARE) with Yttrium-90 (Y90). Before the approval of immune-checkpoint inhibitors, a similar safety profile was reported TARE ST tyrosine kinase inhibitors (TKI). However, whole-liver underlying cirrhosis were identified as risk factors potentially lethal radioembolization-induced liver disease (REILD). Therefore, efficacy atezolizumab/bevacizumab...
Percutaneous image-guided tumor ablation of liver malignancies has become an indispensable therapeutic procedure. The aim this evaluation the prospectively managed multinational registry voluntary German Society for Interventional Radiology and Minimally Invasive Therapy (DeGIR) was to analyze its use, technical success, complications in clinical practice.
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic after first-line sorafenib or lenvatinib was compared a retrospective real-world cohort. In total, 164 HCC were included. Child B cirrhosis present 26 (16.5%), whereas 132 (83.5%) had preserved liver function. 72 (44%) discontinued while 51 (31%) and 31 (19%) received 2 more lines. Most notably, median overall survival...
Introduction: Septic shock is associated with high mortality and hemodynamic impairment. The use of corticoids a common therapeutic tool in critically ill patients. However, data on the mechanisms prognostic ability improvement by adjunctive steroids are rare. This study primarily aimed to evaluate short-term effects hydrocortisone therapy catecholamine requirement hemodynamics derived from transpulmonary thermodilution (TPTD) 30 patients septic 28 days rate 50%. Methods: Hydrocortisone was...
Aim Evaluation of efficacy and safety atezolizumab+bevacizumab in real-world patients with impaired liver function prior systemic therapy.
Introduction Atezolizumab plus bevacizumab (atezo/bev) is the standard of care in first-line systemic therapy for advanced stage hepatocellular carcinoma (aHCC). Data on efficacy and safety atezo/bev patients with aHCC who received previous are not available.